Normax Biomed

Name

Normax Biomed

Legal name

Normax Biomed Limited

Website

https://normaxbiomed.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Personalized mRNA Cancer Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• MRNA cancer immunotherapy
• Personalized neoantigen vaccines
• MRNA vaccine manufacturing
• Contract development manufacturing
• Infectious disease vaccines

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Infrastructure, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Personalized mRNA Cancer Immunotherapy Manufacturing: Manufacturing and delivery of personalized mRNA cancer vaccines for individual cancer patients. The vaccine is designed within 10 weeks of taking tumor biopsy and blood sample, with production taking 1-2 months after tissue samples are collected.
2. CDMO Services (Contract Development and Manufacturing Organization): Normax offers mRNA vaccine manufacturing capabilities as a CDMO to any customer that wants to hire their services. Each Vax Factory can produce approximately 100 million doses per year in single shift operation.
3. Vax Factory Modular Manufacturing: Modular GMP pods that can be assembled at approximately €30 million each. CDMO fee-for-service business estimated average EBITDA 30-40%.
4. mRNA Vaccines for Infectious Diseases: Development and manufacturing of mRNA vaccines for infectious diseases including COVID-19, Tuberculosis, HIV, Malaria at approximately $4 per dose for large scale delivery.
5. Normax AAA mRNA Vaccine Bond: Initial investment for GOAL 2050 (end transmission of TB and HIV by 2050) planned to be generated from private investment in the Normax AAA mRNA Vaccine Bond up to €800 million.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Normax Biomed develops and manufactures personalized precision (n=1) mRNA cancer immunotherapies through its flagship EARTh (Educated Antigen Receptor Therapy) platform, designed to direct a patient's immune response against their specific cancer cells using AI-identified neoantigens. The company also produces mRNA vaccines for infectious diseases (COVID-19, Tuberculosis, HIV, H5N1, Disease-X) and operates modular "Vax Factory" GMP manufacturing pods (each capable of ~100 million doses/year) deployed via a 10-country franchise network and partnerships with leading cancer hospitals.

Product overview

Normax Biomed is a biotechnology company developing personalized mRNA cancer immunotherapies and mRNA vaccines for infectious diseases. The core product portfolio includes EARTh Immunotherapies and My Cancer Immunotherapies (personalized mRNA cancer vaccines targeting patient-specific neoantigens), supported by the Safe AI digital health platform developed with BiocommAI. The company also operates Vax Factory manufacturing infrastructure for mRNA vaccine production and pandemic preparedness. The product pipeline includes vaccine candidates for Universal Coronavirus, Tuberculosis, HIV, H5N1, and Disease-X (emerging pathogen). The BioXP system by Telesis Bio is used for accelerated mRNA vaccine development research.

Differentiator

Problem solved

Functional benefit

Brands

• EARTh Immunotherapies: Personalized mRNA cancer therapy designed to direct the immune response of the patient to attack the specific cancer cells of the patient, based on neoantigens linked with the patient's cancer cells.
• My Cancer Immunotherapies
• Vax Factory
• Normax Extreme Social Impact (ESI)

Products and services

• EARTh Immunotherapies (Educated Antigen Receptor Therapy)

Quantifiable outcome

• 1 in 2 people will probably get cancer within their lifetime
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Medical Technologies Innovation Facility (MTIF) at Nottingham Trent UniversitycoreTechnology or Integration · 24 January 2023Partnership to offer access to BioXp system by Telesis Bio for accelerated development and discovery of new mRNA vaccines and gene therapies. MTIF provides prototype development, laboratory testing, regulatory filing support, and human analysis services.
• Telesis Bio Inc.coreTechnology or Integration · 24 January 2023Provider of BioXp system - the world's first commercially available end-to-end fully automated benchtop synthetic biology workstation for overnight automated synthesis of genes, clones, DNA libraries, and mRNA.
• BiocommAI Inc.coreTechnology or IntegrationStrategic sister company specializing in Safe AI-enabled digital health services for patients and doctors with regulatory compliant AI data centers with mathematically provable Safe AI for healthcare including EARTh GMP Process for personalized mRNA immunotherapy vaccines. BiocommAI is an official member of NIST's U.S. AI Safety Institute Consortium (AISIC).
• City of HopecoreStrategic or Co-development PartnerCalifornia-based cancer hospital partner for personalized mRNA cancer immunotherapy delivery and clinical trials in the US market.
• The Arsène Burny Cancer Institute (ICAB) at CHU de LiègecoreStrategic or Co-development PartnerBelgium cancer institute partnership for EARTh clinical trials and personalized cancer immunotherapy delivery. Clinical trial Principal Investigators include Guy Jerusalem MD and Charles Pottier MD.
• Velindre Cancer Center, University Hospital LlandoughcoreStrategic or Co-development PartnerWelsh cancer center partnership with Principal Investigator Mick Button MD for EARTh clinical trials in the UK.
• Berkeley CommunicationsminorGTM or Marketing PartnerGlobal media agent handling press inquiries and communications (+44 118 909 0909, [email protected]) for UK, EU, and US markets.
• Legal Advisors (Mason Hayes & Curran, CMS, Cooley UK)minorImplementation/ SI/ Consulting PartnerLegal counsel: Mason Hayes & Curran (Dublin), CMS (Zurich), Cooley (London) for listing and regulatory compliance.

Scale indicators11 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Lonza: Global contract development and manufacturing organization (CDMO) with leading mRNA and biologics manufacturing capacity. Highly relevant to Normax's planned Vax Factory CDMO service offering and overall mRNA manufacturing scale.
• Thermo Fisher Scientific: Life sciences tools and services giant with significant mRNA and cell therapy manufacturing services (Patheon). Listed on Normax's website as a strategic collaborator and represents the kind of broad incumbent Normax may eventually partner with or compete against for CDMO share.

Direct peers

• CureVac: mRNA therapeutics company developing cancer vaccines and infectious disease vaccines using proprietary mRNA technology. Direct competitor to Normax in the mRNA modality space, with similar scale and stage.
• BioNTech: Pioneer in individualized mRNA cancer vaccines (BNT122/RO7198457 in collaboration with Genentech) and infectious disease mRNA vaccines. Directly comparable to Normax in both technology platform (personalized neoantigen mRNA) and target customer base (cancer hospitals / oncologists).
• Moderna: mRNA platform leader with oncology program mRNA-4157/V940 (partnered with Merck, Phase 2b/3) and large infectious disease portfolio. Competes head-to-head with Normax in both personalized cancer immunotherapy and pandemic preparedness mRNA vaccines.
• Gritstone bio: Develops neoantigen-based immunotherapies (GRANITE and SLATE programs) for solid tumors using AI-driven tumor neoantigen identification. Closely comparable to Normax's EARTh approach of personalized neoantigen cancer vaccines.
• Arcturus Therapeutics: mRNA medicines company with self-amplifying RNA (saRNA) platform targeting infectious diseases and rare diseases. Comparable to Normax in mRNA manufacturing technology and CDMO-adjacent service model.

Emerging players

• Strand Therapeutics: Synthetic biology / mRNA company developing programmable, self-replicating mRNA therapeutics for oncology. Comparable in the AI-meets-mRNA intersection that Normax is pursuing, though at an earlier stage.
• Adaptimmune: Cell therapy company developing personalized SPEAR T-cells for solid tumors. Competes with Normax in the personalized cancer immunotherapy outcome space, though with a different modality (cell therapy vs. mRNA).
• Personalis: AI-driven genomics and neoantigen identification company (NeXT Personal platform) that supplies tumor molecular profiling to cancer immunotherapy developers. Overlaps with Normax's AI-driven neoantigen discovery layer rather than full-stack vaccine delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/normaxbiomed
• LinkedInlinkedin.com/in/peteralbertjensen

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Normax Biomed